These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 18547851

  • 1. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
    Gani OA, Sylte I.
    J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
    [Abstract] [Full Text] [Related]

  • 2. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W.
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [Abstract] [Full Text] [Related]

  • 3. The human semaphorin 6B gene is down regulated by PPARs.
    Collet P, Domenjoud L, Devignes MD, Murad H, Schohn H, Dauça M.
    Genomics; 2004 Jun; 83(6):1141-50. PubMed ID: 15177567
    [Abstract] [Full Text] [Related]

  • 4. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
    Gani OA, Sylte I.
    Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
    [Abstract] [Full Text] [Related]

  • 5. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G, Torres N, Tovar AR.
    Rev Invest Clin; 2004 Jul; 56(3):351-67. PubMed ID: 15612519
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptors and the metabolic syndrome.
    Bragt MC, Popeijus HE.
    Physiol Behav; 2008 May 23; 94(2):187-97. PubMed ID: 18191967
    [Abstract] [Full Text] [Related]

  • 7. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C, Tsantili-Kakoulidou A, Theocharis S.
    Fundam Clin Pharmacol; 2007 Jun 23; 21(3):231-44. PubMed ID: 17521292
    [Abstract] [Full Text] [Related]

  • 8. Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid.
    Yamazaki Y, Kawano Y, Uebayasi M.
    Life Sci; 2008 Jan 30; 82(5-6):290-300. PubMed ID: 18166202
    [Abstract] [Full Text] [Related]

  • 9. Peroxisome proliferator-activated receptors and retinoid X receptor-alpha in term human gestational tissues: tissue specific and labour-associated changes.
    Holdsworth-Carson SJ, Permezel M, Riley C, Rice GE, Lappas M.
    Placenta; 2009 Feb 30; 30(2):176-86. PubMed ID: 19070893
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptors and their relevance to dermatology.
    Friedmann PS, Cooper HL, Healy E.
    Acta Derm Venereol; 2005 Feb 30; 85(3):194-202. PubMed ID: 16040401
    [Abstract] [Full Text] [Related]

  • 11. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P, Fruchart JC, Staels B.
    Nat Clin Pract Endocrinol Metab; 2007 Feb 30; 3(2):145-56. PubMed ID: 17237841
    [Abstract] [Full Text] [Related]

  • 12. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.
    Collino M, Patel NS, Thiemermann C.
    Ther Adv Cardiovasc Dis; 2008 Jun 30; 2(3):179-97. PubMed ID: 19124421
    [Abstract] [Full Text] [Related]

  • 13. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD.
    Ann N Y Acad Sci; 2006 Nov 30; 1083():306-18. PubMed ID: 17148746
    [Abstract] [Full Text] [Related]

  • 14. [PPARs: structure, mechanisms of action and control. Note I].
    Filip-Ciubotaru F, Foia L, Manciuc C, Grigore C.
    Rev Med Chir Soc Med Nat Iasi; 2011 Nov 30; 115(2):477-84. PubMed ID: 21870744
    [Abstract] [Full Text] [Related]

  • 15. Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor α, β, γ subtypes: an in silico approach.
    Sarath Josh MK, Pradeep S, Vijayalekshmi Amma KS, Balachandran S, Abdul Jaleel UC, Doble M, Spener F, Benjamin S.
    J Appl Toxicol; 2014 Jul 30; 34(7):754-65. PubMed ID: 23843199
    [Abstract] [Full Text] [Related]

  • 16. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
    Itoh T, Murota I, Yoshikai K, Yamada S, Yamamoto K.
    Bioorg Med Chem; 2006 Jan 01; 14(1):98-108. PubMed ID: 16198578
    [Abstract] [Full Text] [Related]

  • 17. Cloning and expression pattern of peroxisome proliferator-activated receptors, estrogen receptor alpha and retinoid X receptor alpha in the thicklip grey mullet Chelon labrosus.
    Raingeard D, Cancio I, Cajaraville MP.
    Comp Biochem Physiol C Toxicol Pharmacol; 2009 Jan 01; 149(1):26-35. PubMed ID: 18619562
    [Abstract] [Full Text] [Related]

  • 18. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes.
    Tan NS, Michalik L, Desvergne B, Wahli W.
    J Steroid Biochem Mol Biol; 2005 Feb 01; 93(2-5):99-105. PubMed ID: 15860251
    [Abstract] [Full Text] [Related]

  • 19. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.
    Mahindroo N, Peng YH, Lin CH, Tan UK, Prakash E, Lien TW, Lu IL, Lee HJ, Hsu JT, Chen X, Liao CC, Lyu PC, Chao YS, Wu SY, Hsieh HP.
    J Med Chem; 2006 Oct 19; 49(21):6421-4. PubMed ID: 17034149
    [Abstract] [Full Text] [Related]

  • 20. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
    Gani OA.
    Cardiovasc Diabetol; 2008 Mar 20; 7():6. PubMed ID: 18355413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.